Bone marrow dosimetry in low volume mHSPC patients receiving Lu-177-PSMA therapy using SPECT/CT.

ABSTRACT:

Background

Bone marrow toxicity in advanced prostate cancer patients who receive [¹⁷⁷Lu]Lu-PSMA-617 is a well-known concern. In early stage patients; e.g. low volume metastatic hormone sensitive prostate cancer (mHSPC) patients, prevention of late bone marrow toxicity is even more crucial due to longer life expectancy. To date, bone marrow dosimetry is primarily performed using blood sampling. This method is time consuming and does not account for possible active bone marrow uptake. Therefore other methodologies are investigated. We calculated the bone marrow absorbed dose for [¹⁷⁷Lu]Lu-PSMA-617 in mHSPC patients using SPECT/CT imaging and compared it to the blood sampling method as reference.

Methods

Eight mHSPC patients underwent two cycles (3 and 6 G

SUBMITTER: Grob D 

PROVIDER: S-EPMC10991600 | biostudies-literature | 2024 Apr

REPOSITORIES: biostudies-literature